

William J Muller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9578419/publications.pdf>

Version: 2024-02-01

124
papers

12,449
citations

36203

51
h-index

25716

108
g-index

124
all docs

124
docs citations

124
times ranked

15828
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. <i>Cell</i> , 1988, 54, 105-115.	13.5	1,097
2	Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases. <i>American Journal of Pathology</i> , 2003, 163, 2113-2126.	1.9	912
3	Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer. <i>Cancer Cell</i> , 2013, 24, 213-228.	7.7	678
4	Suppression of tumor growth and metastasis in Mgat5-deficient mice. <i>Nature Medicine</i> , 2000, 6, 306-312.	15.2	511
5	$\alpha 24$ Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis. <i>Cell</i> , 2006, 126, 489-502.	13.5	418
6	Transforming growth factor $\beta 2$ signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8430-8435.	3.3	409
7	Targeted disruption of $\alpha 1$ -integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. <i>Cancer Cell</i> , 2004, 6, 159-170.	7.7	385
8	Mammalian Grb2 Regulates Multiple Steps in Embryonic Development and Malignant Transformation. <i>Cell</i> , 1998, 95, 793-803.	13.5	345
9	Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway. <i>Molecular and Cellular Biology</i> , 2000, 20, 672-683.	1.1	342
10	Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. <i>Nature Genetics</i> , 2007, 39, 338-346.	9.4	284
11	Activation of Akt (Protein Kinase B) in Mammary Epithelium Provides a Critical Cell Survival Signal Required for Tumor Progression. <i>Molecular and Cellular Biology</i> , 2001, 21, 2203-2212.	1.1	262
12	CD44v3,8-10 is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. <i>Journal of Cellular Physiology</i> , 1998, 176, 206-215.	2.0	249
13	Activation of Akt-1 (PKB β) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis but Suppresses Tumor Invasion. <i>Cancer Research</i> , 2004, 64, 3171-3178.	0.4	235
14	Effect of Conditional Knockout of the Type II TGF- $\beta 2$ Receptor Gene in Mammary Epithelia on Mammary Gland Development and Polyomavirus Middle T Antigen Induced Tumor Formation and Metastasis. <i>Cancer Research</i> , 2005, 65, 2296-2302.	0.4	229
15	Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. , 1998, 77, 640-644.		226
16	Insights from transgenic mouse models of ERBB2-induced breast cancer. <i>Nature Reviews Cancer</i> , 2007, 7, 389-397.	12.8	222
17	Requirement for Both Shc and Phosphatidylinositol 3-kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis. <i>Molecular and Cellular Biology</i> , 1998, 18, 2344-2359.	1.1	189
18	Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20302-20307.	3.3	184

#	ARTICLE	IF	CITATIONS
19	Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior. <i>Clinical and Experimental Metastasis</i> , 2005, 22, 47-59.	1.7	182
20	The Role of the Epidermal Growth Factor Receptor Family in Mammary Tumorigenesis and Metastasis. <i>Experimental Cell Research</i> , 1999, 253, 78-87.	1.2	168
21	Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression. <i>Cancer Research</i> , 2009, 69, 5057-5064.	0.4	154
22	Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer. <i>Molecular and Cellular Biology</i> , 2001, 21, 1540-1551.	1.1	147
23	Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1 and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. <i>Oncogene</i> , 1999, 18, 1663-1676.	2.6	138
24	Distinct Biological Roles for the Akt Family in Mammary Tumor Progression. <i>Cancer Research</i> , 2010, 70, 4260-4264.	0.4	138
25	ShcA signalling is essential for tumour progression in mouse models of human breast cancer. <i>EMBO Journal</i> , 2008, 27, 910-920.	3.5	131
26	Transgenic mouse models of human breast cancer. <i>Oncogene</i> , 2000, 19, 6130-6137.	2.6	130
27	The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. <i>Cell Reports</i> , 2018, 23, 1476-1490.	2.9	127
28	Activated neu Induces Rapid Tumor Progression. <i>Journal of Biological Chemistry</i> , 1996, 271, 7673-7678.	1.6	121
29	The p110 ^α and p110 ^β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. <i>Genes and Development</i> , 2012, 26, 1573-1586.	2.7	116
30	Mammary epithelial-specific expression of the integrin linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. <i>Oncogene</i> , 2001, 20, 7064-7072.	2.6	115
31	PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. <i>Journal of Clinical Investigation</i> , 2011, 121, 4655-4669.	3.9	110
32	HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation. <i>Cancer Research</i> , 2012, 72, 2672-2682.	0.4	106
33	Identification of a Stat3-Dependent Transcription Regulatory Network Involved in Metastatic Progression. <i>Cancer Research</i> , 2009, 69, 6823-6830.	0.4	96
34	Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. <i>Oncogene</i> , 2002, 21, 890-898.	2.6	94
35	Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo. <i>Oncogene</i> , 2021, 40, 475-491.	2.6	91
36	Signal transduction in mammary tumorigenesis: a transgenic perspective. <i>Oncogene</i> , 2000, 19, 1038-1044.	2.6	87

#	ARTICLE	IF	CITATIONS
37	STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. <i>Cancer Research</i> , 2016, 76, 1416-1428.	0.4	87
38	β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. <i>Breast Cancer Research</i> , 2011, 13, 229.	2.2	80
39	Multifaceted Roles of Integrins in Breast Cancer Metastasis. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2007, 12, 135-142.	1.0	79
40	Transcriptional Control of the ERBB2 Amplicon by ERRα and PGC-1β Promotes Mammary Gland Tumorigenesis. <i>Cancer Research</i> , 2010, 70, 10277-10287.	0.4	78
41	CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. <i>JCI Insight</i> , 2019, 4, .	2.3	77
42	Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins. <i>Journal of Biological Chemistry</i> , 2001, 276, 38921-38928.	1.6	74
43	Integrins in mammary-stem-cell biology and breast-cancer progression – a role in cancer stem cells?. <i>Journal of Cell Science</i> , 2009, 122, 207-214.	1.2	74
44	Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. <i>Cancer Research</i> , 2016, 76, 4752-4764.	0.4	71
45	The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. <i>Oncogene</i> , 2005, 24, 7599-7607.	2.6	68
46	PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis. <i>Journal of Biological Chemistry</i> , 2009, 284, 19018-19026.	1.6	66
47	β-Catenin Signaling Is a Critical Event in ErbB2-Mediated Mammary Tumor Progression. <i>Cancer Research</i> , 2013, 73, 4474-4487.	0.4	65
48	Bcl3 Selectively Promotes Metastasis of ERBB2-Driven Mammary Tumors. <i>Cancer Research</i> , 2013, 73, 745-755.	0.4	63
49	Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. <i>Nature Communications</i> , 2018, 9, 2547.	5.8	63
50	Translational and HIF-1-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. <i>Cell Metabolism</i> , 2018, 28, 817-832.e8.	7.2	61
51	Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. , 1998, 77, 937-941.		58
52	c-Src-null mice exhibit defects in normal mammary gland development and ERα signaling. <i>Oncogene</i> , 2005, 24, 5629-5636.	2.6	58
53	c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential. <i>Molecular and Cellular Biology</i> , 2009, 29, 5858-5871.	1.1	57
54	Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. <i>Breast Cancer Research</i> , 2017, 19, 74.	2.2	55

#	ARTICLE	IF	CITATIONS
55	Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. <i>Cancer Research</i> , 2003, 63, 4920-6.	0.4	53
56	Copy Number Aberrations in Mouse Breast Tumors Reveal Loci and Genes Important in Tumorigenic Receptor Tyrosine Kinase Signaling. <i>Cancer Research</i> , 2005, 65, 9695-9704.	0.4	52
57	The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. <i>Nature Communications</i> , 2017, 8, 14638.	5.8	52
58	Estradiol Promotes Growth and Angiogenesis in Polyoma Middle T Transgenic Mouse Mammary Tumor Explants. <i>Breast Cancer Research and Treatment</i> , 2003, 78, 1-6.	1.1	51
59	Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2808-2813.	3.3	50
60	The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis. <i>Breast Cancer Research</i> , 2016, 18, 131.	2.2	50
61	Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development. <i>Molecular and Cellular Biology</i> , 2007, 27, 6361-6371.	1.1	49
62	Detection of amphiregulin and Cripto-1 in mammary tumors from transgenic mice. , 1996, 15, 44-56.		48
63	Signal Transduction in Transgenic Mouse Models of Human Breast Cancer—Implications for Human Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 323-335.	1.0	45
64	Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis. <i>Cancer Research</i> , 2008, 68, 2122-2131.	0.4	45
65	PGC-1 α Promotes the Growth of ErbB2/Neu-Induced Mammary Tumors by Regulating Nutrient Supply. <i>Cancer Research</i> , 2012, 72, 1538-1546.	0.4	45
66	Progressive polarity loss and luminal collapse disrupt tissue organization in carcinoma. <i>Genes and Development</i> , 2017, 31, 1573-1587.	2.7	45
67	LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. <i>Cancer & Metabolism</i> , 2013, 1, 18.	2.4	44
68	Cancer Affects microRNA Expression, Release, and Function in Cardiac and Skeletal Muscle. <i>Cancer Research</i> , 2014, 74, 4270-4281.	0.4	44
69	Mammary gland neoplasia: insights from transgenic mouse models. <i>BioEssays</i> , 2000, 22, 554-563.	1.2	40
70	A novel role for 14-3-3 σ in regulating epithelial cell polarity. <i>Genes and Development</i> , 2010, 24, 947-956.	2.7	40
71	Accelerated Mammary Tumor Development in Mutant Polyomavirus Middle T Transgenic Mice Expressing Elevated Levels of Either the Shc or Grb2 Adapter Protein. <i>Molecular and Cellular Biology</i> , 1999, 19, 8169-8179.	1.1	39
72	p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt/ β -Catenin Signaling. <i>Cancer Research</i> , 2006, 66, 8529-8541.	0.4	39

#	ARTICLE	IF	CITATIONS
73	p120-catenin is essential for terminal end bud function and mammary morphogenesis. <i>Development</i> (Cambridge), 2012, 139, 1754-1764.	1.2	39
74	Tumoral Vitamin D Synthesis by CYP27B1 1- β -Hydroxylase Delays Mammary Tumor Progression in the PyMT-MMTV Mouse Model and Its Action Involves NF- κ B Modulation. <i>Endocrinology</i> , 2016, 157, 2204-2216.	1.4	37
75	Stat3 regulates centrosome clustering in cancer cells via Stathmin/PLK1. <i>Nature Communications</i> , 2017, 8, 15289.	5.8	36
76	Activation Of The Src Family Of Tyrosine Kinases In Mammary Tumorigenesis. <i>Advances in Cancer Research</i> , 1994, 64, 111-123.	1.9	35
77	Functional Redundancy between β 1 and β 3 Integrin in Activating the IR/Akt/mTORC1 Signaling Axis to Promote ErbB2-Driven Breast Cancer. <i>Cell Reports</i> , 2019, 29, 589-602.e6.	2.9	35
78	Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: An animal model for CEA-directed tumor immunotherapy. , 1997, 72, 197-202.		33
79	Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition. <i>Molecular and Cellular Biology</i> , 2015, 35, 4069-4082.	1.1	33
80	Mouse Models of Overexpression Reveal Distinct Oncogenic Roles for Different Type I Protein Arginine Methyltransferases. <i>Cancer Research</i> , 2019, 79, 21-32.	0.4	32
81	Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression. <i>Cancer Research</i> , 2016, 76, 2662-2674.	0.4	31
82	Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and β PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4670-4681.	3.2	31
83	Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. <i>Cell Reports</i> , 2019, 29, 249-257.e8.	2.9	29
84	ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. <i>Nature Communications</i> , 2022, 13, 2011.	5.8	29
85	Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression. <i>Oncogene</i> , 2003, 22, 9151-9155.	2.6	28
86	The induction of uterine leiomyomas and mammary tumors in transgenic mice expressing polyomavirus (PyV) large T (LT) antigen is associated with the ability of PyV LT antigen to form specific complexes with retinoblastoma and CUTL1 family members. <i>Oncogene</i> , 1998, 16, 1963-1972.	2.6	26
87	Loss of the 14-3-3 β Tumor Suppressor Is a Critical Event in ErbB2-Mediated Tumor Progression. <i>Cancer Discovery</i> , 2012, 2, 68-81.	7.7	26
88	The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. <i>Cancer Research</i> , 2003, 63, 3395-402.	0.4	26
89	Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response. <i>Cancer Research</i> , 2010, 70, 7776-7787.	0.4	25
90	An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. <i>Nature Communications</i> , 2019, 10, 2901.	5.8	24

#	ARTICLE	IF	CITATIONS
91	Oncogenic Activating Mutations in the neu/erbB-2 Oncogene Are Involved in the Induction of Mammary Tumors. <i>Annals of the New York Academy of Sciences</i> , 1999, 889, 45-51.	1.8	23
92	Distinct ErbB-2-Coupled Signaling Pathways Promote Mammary Tumors with Unique Pathologic and Transcriptional Profiles. <i>Cancer Research</i> , 2007, 67, 7579-7588.	0.4	23
93	Integrins in breast cancer dormancy. <i>Apmis</i> , 2008, 116, 677-684.	0.9	23
94	Uncoupling of PI3K from ErbB3 Impairs Mammary Gland Development but Does Not Impact on ErbB2-Induced Mammary Tumorigenesis. <i>Cancer Research</i> , 2012, 72, 3080-3090.	0.4	23
95	Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo. <i>Breast Cancer Research</i> , 2012, 14, R36.	2.2	23
96	Marine fish oil is more potent than plant-based n-3 polyunsaturated fatty acids in the prevention of mammary tumors. <i>Journal of Nutritional Biochemistry</i> , 2018, 55, 41-52.	1.9	23
97	Î2-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E707-E716.	3.3	22
98	Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression. <i>Breast Cancer Research</i> , 2014, 16, R11.	2.2	21
99	A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor Î± expressed from an adenovirus vector induces an antitumor response with reduced toxicity. <i>Cancer Gene Therapy</i> , 1999, 6, 465-474.	2.2	18
100	Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. <i>Development (Cambridge)</i> , 2004, 131, 5551-5560.	1.2	15
101	Transgenic models of breast cancer metastasis. <i>Cancer Treatment and Research</i> , 1996, 83, 71-88.	0.2	15
102	Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity. <i>Breast Cancer Research</i> , 2015, 17, 7.	2.2	14
103	Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. <i>JCI Insight</i> , 2022, 7, .	2.3	14
104	<i>In vivo</i> evidence supporting a metastasis suppressor role for <i>Stard13</i> (<i>Dlc2</i>) in <i>ErbB2</i> (<i>Neu</i>) oncogene induced mouse mammary tumors. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 182-191.	1.5	13
105	Deletion of Cd151 reduces mammary tumorigenesis in the MMTV/PyMT mouse model. <i>BMC Cancer</i> , 2014, 14, 509.	1.1	12
106	Tetraspanin CD9 is Regulated by miR-518f-5p and Functions in Breast Cell Migration and In Vivo Tumor Growth. <i>Cancers</i> , 2020, 12, 795.	1.7	11
107	ERBB2 Deficiency Alters an E2F-1-Dependent Adaptive Stress Response and Leads to Cardiac Dysfunction. <i>Molecular and Cellular Biology</i> , 2014, 34, 4232-4243.	1.1	10
108	Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR. <i>Cell Reports</i> , 2020, 31, 107571.	2.9	10

#	ARTICLE	IF	CITATIONS
109	Point-activated ESR1 ^{Y541S} has a dramatic effect on the development of sexually dimorphic organs. <i>Genes and Development</i> , 2020, 34, 1304-1309.	2.7	10
110	Pharmacological or genetic inhibition of iNOS prevents cachexia-mediated muscle wasting and its associated metabolism defects. <i>EMBO Molecular Medicine</i> , 2021, 13, e13591.	3.3	9
111	Fish oil supplementation increases expression of mammary tumor apoptosis mediators and reduces inflammation in an obesity-associated HER-2 breast cancer model. <i>Journal of Nutritional Biochemistry</i> , 2021, 95, 108763.	1.9	9
112	Emergence of β 1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvironment. <i>Oncogene</i> , 2022, 41, 527-537.	2.6	9
113	An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis. <i>Bone Research</i> , 2020, 8, 28.	5.4	8
114	In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches. <i>Advances in Cancer Research</i> , 2020, 147, 189-228.	1.9	7
115	Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib. <i>Oncotarget</i> , 2018, 9, 33382-33395.	0.8	7
116	Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance. <i>Molecular Cancer Research</i> , 2018, 16, 894-908.	1.5	6
117	Exploiting Mouse Models to Recapitulate Clinical Tumor Dormancy and Recurrence in Breast Cancer. <i>Endocrinology</i> , 2022, 163, .	1.4	6
118	Her-2 Breast Cancer Outcomes Are Mitigated by Consuming n-3 Polyunsaturated, Saturated, and Monounsaturated Fatty Acids Compared to n-6 Polyunsaturated Fatty Acids. <i>Nutrients</i> , 2020, 12, 3901.	1.7	5
119	CD44 ^{v3,810} is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. <i>Journal of Cellular Physiology</i> , 1998, 176, 206-215.	2.0	4
120	Oncogene Mediated Signal Transduction in Transgenic Mouse Models of Human Breast Cancer. , 2000, 480, 185-194.		2
121	Abstract PS17-31: Investigating the estrogen receptor Y537S mutation in transgenic models of luminal B breast cancer. , 2021, , .		2
122	Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer. <i>Oncogene</i> , 2022, 41, 3445-3451.	2.6	2
123	Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: An animal model for CEA-directed tumor immunotherapy. , 1997, 72, 197.		1
124	Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. , 1998, 77, 937.		1